Related Experiment Video
Updated: Feb 14, 2026

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
Published on: March 29, 2024
Genetic Variants Identified from GWAS for Predisposition to Type 2 Diabetes Predict Sulfonylurea Drug Response
N M Phani1, M Vohra1, P Adhikari2
1Department of Biotechnology, School of Life Sciences, Manipal Academy of Higher Education, Manipal- 576104, Karnataka, India.
Background:
Several SNPs were identified through GWAS for their association with type 2 diabetes which has implications to pancreatic β-cell physiology.
Objective:
We aimed to study the role of risk alleles of TCF7L2, KCNJ11, CDKN2A, CDKAL1, IGF2BP2, SLC30A8 and KCNQ1 along with pharmacokinetic variants in response to sulfonylureas.
Method:
We performed a prospective study on 209 newly diagnosed subjects; treatment naive T2D subjects were recruited. Individuals were started with glibenclamide monotherapy and followed-up for 12 weeks. Genotyping was done, using PCR-RFLP and TETRA-ARMS PCR and confirmed by DNA sequencing.
Results:
In univariate regression analysis, KCNJ11 (rs5219) was only the predictor for glibenclamide treatment failure.
Conclusion:
The present data suggests a possible role of KCNJ11 gene in altered response to glibenclamide.
Related Concept Videos
Principles of Pharmacogenetics: Types of Genetic Variants
Diabetes Mellitus: Type 2 and Gestational
Types of Genetic Transfer Between Organisms
Types of Genetic Transfer Between Organisms
Predicting Products: SN1 vs. SN2
With increased substitution on the alkyl halide,...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

